A5091089490- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Chronic Myeloid Leukemia Treatments
- Cancer therapeutics and mechanisms
- Oral health in cancer treatment
- Transplantation: Methods and Outcomes
- Chemotherapy-induced organ toxicity mitigation
- Immunotherapy and Immune Responses
- Mesenchymal stem cell research
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Protein Degradation and Inhibitors
- Multiple and Secondary Primary Cancers
- Neuroendocrine Tumor Research Advances
The Barbara Ann Karmanos Cancer Institute
2015-2024
Wayne State University
2015-2024
Harper University Hospital
2024
Michigan United
2018
University of Minnesota Medical Center
2017
University of Michigan
2001-2006
Michigan Medicine
2003
Harvard University
1991-2001
Dana-Farber Cancer Institute
1991-2001
Ann Arbor VA Medical Center
2001
The study was designed to determine the duration of complete response (CR) for patients with unresectable or metastatic breast cancer treated high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) while responding conventional-dose therapy.Eligibility criteria included histologically documented cancer, at least a partial (PR) therapy, no prior pelvic radiotherapy, cumulative doxorubicin less than 500 mg/m3, physiologic age between 18 55 years. Patients inadequate renal, hepatic,...
We reviewed the clinical outcome of 8 patients with steroid-refractory chronic graft-versus-host disease (GVHD) who received an anti-CD20 chimeric monoclonal antibody (rituximab). Rituximab was given by intravenous infusion at a weekly dose 375 mg/m2 for 4 weeks. All had extensive treatment various immunosuppressive agents; 6 also extracorporeal photopheresis. GVHD diffuse or localized sclerodermoid and xerophthalmia. Other extracutaneous involvements included cold agglutinin Raynaud...
Cyclophosphamide, which forms the nucleus for virtually all preparative regimens autologous bone marrow transplantation (ABMT), is an alkylating agent of cytotoxicity not directly caused by parent compound but its biologically active metabolites. Its nonmyelosuppressive toxicity in ABMT setting cardiomyopathy. We attempted to determine any correlation between plasma levels total cyclophosphamide and subsequent development cardiac dysfunction.Analyses derivation concentration-time curves...
PURPOSE Twenty-seven percent of responding metastatic breast cancer patients remain progression-free a median 29 months following one intensification course cyclophosphamide (6,000 mg/m2), thiotepa (500 and carboplatin (800 mg/m2) (CTCb) with autologous bone marrow transplantation (ABMT). European investigators report high complete response (CR) rates melphalan for cancer. This trial studied the feasibility two tandem high-dose therapies in an attempt to optimize disease duration. PATIENTS...
PURPOSE With a median observation time of 50 months from transplant, 13 (22%) 62 women with metastatic breast cancer treated high-dose chemotherapy at the Dana-Farber Cancer Institute (DFCI)/Beth Israel Hospital (BIH) remain progression-free. This study determined factors prognostic for prolonged progression-free survival (PFS). METHODS From June 1988 to January 1992, who responded standard received cyclophosphamide, thiotepa, and carboplatin autotransplantation. Data encompassing initial...
Clinical and preclinical data indicate that tumor necrosis factor (TNF)-alpha is an important mediator of acute graft-versus-host disease (aGVHD) after allogeneic bone marrow transplantation. We completed a study using etanercept, fusion protein capable neutralizing TNF-alpha, for the initial treatment aGVHD. Etanercept (25 mg subcutaneously) was administered twice weekly 16 doses, along with methylprednisolone (2 mg/kg) tacrolimus biopsy-proven Twenty patients median age 47 years (range,...
Retrospective review of 291 solid tumor and lymphoma patients undergoing autologous bone marrow transplantation (BMT) was performed to determine the influence pretransplant characteristics preparative regimen development hepatic venoocclusive disease (VOD). Twelve (4.1%) developed a clinical syndrome right upper quadrant (RUQ) tenderness or hepatomegaly, jaundice, ascites, with without encephalopathy, within 40 days reinfusion. Evidence metastatic liver only characteristic predictive for VOD...
Both acute and chronic graft-versus-host disease (GVHD) are major causes of morbidity mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). The optimal pharmacological regimen for GVHD prophylaxis is unclear, but combinations a calcineurin inhibitor (cyclosporin or tacrolimus [Tac]) an antimetabolite (methotrexate mycophenolate mofetil [MMF]) typically used. We retrospectively evaluated the clinical outcomes 414 consecutive who underwent AHSCT from...
PURPOSE We examined a consecutive series of 78 patients with non-Hodgkin's lymphoma treated on prospective protocols high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) plus autotransplantation to determine prognostic factors for time treatment failure. PATIENTS AND METHODS Patients relapsed, refractory, or poor-risk intermediate- high-grade were CBV autologous marrow peripheral-blood progenitor cell support. Patient characteristics before transplantation in univariate...
A phase I trial of infusing anti-CD3 × anti-CD20 bispecific antibody (CD20Bi) armed activated T cells (aATC) was conducted in high-risk/refractory non-Hodgkin's lymphoma patients to determine whether aATC infusions are safe, affect immune recovery, and induce an antilymphoma effect. Ex vivo expanded ATC from 12 were with antibody, cryopreserved, infused after autologous stem cell transplantation (SCT). Patients underwent SCT high-dose chemotherapy, started on day +4. The received 1 infusion...
Pleural effusion is a known entity in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT); however, the incidence, risk factors, and morbidity-mortality outcomes associated with pleural effusions remain unknown. We retrospectively evaluated 618 consecutive adult who underwent HSCT from January 2008 to December 2013 at our institution. Seventy one developed median of 40 days (range, 1 - 869) post-HSCT cumulative incidence 9.9% (95% CI, 7.7 12.5%) year. Infectious...
PURPOSE Women with locally unresectable and inflammatory breast carcinoma (IBC) have an approximately 30% 5-year disease-free survival (DFS) rate conventional multimodality therapy. A short but dose-intensive phase II trial was designed in attempt to improve outcome stage IIIB disease. Mastectomy performed after high-dose therapy evaluate pathologic response treatment. METHODS newly diagnosed disease received four 2-week cycles of doxorubicin 90 mg/m2 granulocyte colony-stimulating factor...
Journal Article Intensive Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer Get access Anthony D. Elias, Elias Department of MedicineBoston, Mass M.D., Dana-Farber Institute, 44 Binney St., Boston, MA 02115. Search other works by this author on: Oxford Academic PubMed Google Scholar Lois Ayash, Ayash Emil Frei, III, III Arthur T. Skarin, Skarin Myla Hunt, Hunt Division BiostatisticsBoston, Cathy Wheeler, Wheeler Beth Isreal Hospital, Harvard Medical SchoolBoston, Gary...
Reduced conditioning intensity has extended the option of allogeneic hematopoietic stem cell transplantation to patients who cannot tolerate fully myeloablative regimens. However, relapse and graft-versus-host disease (GVHD) continue be major causes morbidity mortality. We prospectively tested whether a moderate reduction preparative regimen would lead significant in regimen-related toxicity without compromising tumor control cohort 44 ineligible for conventional transplantation. Patients...
Limited information is available on the efficacy of post-transplantation cyclophosphamide (PTcy) or thymoglobulin for graft-versus-host disease (GVHD) prophylaxis in mismatched unrelated donor (MMUD) transplants. We retrospectively compared outcomes 76 adult patients with acute myelogenous leukemia (AML) myelodysplastic syndrome (MDS) who underwent 7/8 HLA-MMUD transplantation and received either PTcy (50 mg/kg day 3 4) (total dose 4.5 mg/kg) GVHD prophylaxis. In addition, tacrolimus...
To determine progression-free survival (PFS) and overall long-term for limited-stage small-cell lung cancer (SCLC) patients aged 60 years or younger who respond to first-line chemotherapy followed by high-dose combination alkylating agents (cyclophosphamide 5,625 mg/m(2), cisplatin 165 carmustine 480 mg/m(2)) with hematologic stem-cell support chest prophylactic cranial radiotherapy.Patients were selected on the basis of their continued response therapy, relative lack significant...
Twenty-one percent of responding metastatic breast cancer patients remain progression-free a median 50 months following one intensification cycle cyclophosphamide (6,000 mg/m2), thiotepa (500 mg/ m2), and carboplatin (800 mg/m2) (CTCb) with autologous bone marrow transplantation (ABMT). This trial studied whether the sequence high-dose melphalan followed by CTCb resulted in improved disease response duration.Women at least partial responses (PRS) to induction received (140 or 180 m2)...
The dose-limiting toxicity in two separate phase I trials of the high-dose single agents ifosfamide and carboplatin was renal insufficiency at 18 g/m2 hepatic ototoxicity 2,400 mg/m2, respectively. In this study, 16 adults were treated with 75% single-agent maximum-tolerated dose (MTD) (12 g/m2) escalating doses (400 to 1,600 mg/m2) determine nonhematologic combination. Both drugs as well mesna for uroprotection given by continuous infusion over 4 days an additional day (total per course, 15...